AbbVie delivered a strong Q3 with sales of $17.404 billion and adjusted EPS of $3.82, topping expectations. The company raised 2026 guidance to $67.8 billion in revenue and $13.95-$13.99 in adjusted EPS, signaling sustained momentum across its portfolio. Pre-market trading moved modestly higher as analysts bumped target prices to $325–$338, underscoring a constructive sentiment shift for ABBV near term.
AbbVie posted a solid Q3 2026 with $17.404 billion in sales, up 10.3% year over year, and adjusted EPS of $3.82, above the $3.75 consensus. The company also raised its full-year outlook, signaling durable momentum. This earnings beat could support further near-term upside as investors reassess growth drivers and free cash flow potential.
AbbVie disclosed that the FDA granted two Breakthrough Therapy Designations for telisotuzumab adizutecan, signaling accelerated development potential for a key oncology candidate. The news contributed to a 1.7% stock advance, reflecting investor optimism about AbbVie's pipeline and potential near-term upside from faster regulatory pathways and potential future collaborations or licensing milestones.
Genmab and AbbVie reported positive late-stage results for a lymphoma combo in newly diagnosed patients, reducing the risk of progression or death. The findings bolster AbbVie's oncology strategy via the Genmab collaboration and could influence future milestones and royalties. If the data hold up, a clear path to regulatory filing may lift ABBV stock in the near term.
AbbVie’s FDA approval of JUVMO for Parkinson’s disease introduces a new growth catalyst to its portfolio, potentially expanding revenue and pipeline value. The initial market reaction was modest, with ABBV up 0.7% to $266.28, amid notable trader commentary highlighting ABBV as a final-trade pick. Uptake, label scope, and competitive dynamics will determine the magnitude of the long‑term upside.
AbbVie won FDA approval for Juvmo (tavapadon), a selective D1/D5 receptor agonist for Parkinson’s, and plans a U.S. launch in October 2026. The TEMPO Phase 3 program supported its efficacy and safety in both early PD and as an adjunct to levodopa, positioning Juvmo as a potential long-term growth driver for AbbVie’s PD franchise. Near-term prospects hinge on Medicare coverage timing and formulary access.
